Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.95 ^USD	+1.22%		+0.20%	-29.08%

Apr. 02	Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target	MT
Mar. 18	Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	CI

Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 11, 2024 at 04:16 pm EDT

Olema Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 96.66 million compared to USD 104.79 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 2.62 a year ago.

Latest news about Olema Pharmaceuticals, Inc.

Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target	Apr. 02	MT
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
HC Wainwright Adjusts Price Target on Olema Pharmaceuticals to $25 From $28, Maintains Buy Rating	Mar. 12	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	Mar. 06	CI
Citigroup Initiates Olema Pharmaceuticals at Buy With $20 Price Target	Jan. 30	MT
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	Jan. 08	CI
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	Dec. 18	CI
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	Dec. 05	CI
Transcript : Olema Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 01:20 PM	Nov. 29
Olema Pharmaceuticals Insider Sold Shares Worth $269,656, According to a Recent SEC Filing	Nov. 24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $824,134, According to a Recent SEC Filing	Nov. 24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $196,233, According to a Recent SEC Filing	Nov. 24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $209,296, According to a Recent SEC Filing	Nov. 24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $117,740, According to a Recent SEC Filing	Nov. 24	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Olema Pharmaceuticals Insider Sold Shares Worth $379,450, According to a Recent SEC Filing	Nov. 03	MT
JPMorgan Adjusts Olema Pharmaceuticals' Price Target to $25 From $19, Maintains Overweight Rating	23-10-24	MT
Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating	23-10-24	MT
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant	23-10-23	CI
Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors	23-10-17	CI
Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress	23-10-16	CI
Olema Pharmaceuticals Says Preclinical Data Show KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity	23-10-12	MT
Olema Pharmaceuticals Broadens Clinical Collaboration With Novartis to Increase Size of Breast Cancer Study	23-10-10	MT

Chart Olema Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.95 USD

Average target price

25 USD

Spread / Average Target

+151.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OLEMA PHARMACEUTICALS, INC.	-29.08%	556M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research